BRPI1009922A2 - uso de um composto derivado de ácido graxo poli-insaturado,composição farmacêutica,e, método para tratar ou provenir dano nem nervo. - Google Patents

uso de um composto derivado de ácido graxo poli-insaturado,composição farmacêutica,e, método para tratar ou provenir dano nem nervo.

Info

Publication number
BRPI1009922A2
BRPI1009922A2 BRPI1009922A BRPI1009922A BRPI1009922A2 BR PI1009922 A2 BRPI1009922 A2 BR PI1009922A2 BR PI1009922 A BRPI1009922 A BR PI1009922A BR PI1009922 A BRPI1009922 A BR PI1009922A BR PI1009922 A2 BRPI1009922 A2 BR PI1009922A2
Authority
BR
Brazil
Prior art keywords
damaging
treating
pharmaceutical composition
fatty acid
acid derivative
Prior art date
Application number
BRPI1009922A
Other languages
English (en)
Portuguese (pt)
Inventor
Adam Kelliher
Angus Morrison
Norman Cameron
Phil Knowles
Original Assignee
Equateq Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Equateq Ltd filed Critical Equateq Ltd
Publication of BRPI1009922A2 publication Critical patent/BRPI1009922A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI1009922A 2009-05-01 2010-04-22 uso de um composto derivado de ácido graxo poli-insaturado,composição farmacêutica,e, método para tratar ou provenir dano nem nervo. BRPI1009922A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0907601.9A GB0907601D0 (en) 2009-05-01 2009-05-01 Novel methods
PCT/GB2010/000817 WO2010125330A1 (en) 2009-05-01 2010-04-22 Use of pufas to treat nerve damage

Publications (1)

Publication Number Publication Date
BRPI1009922A2 true BRPI1009922A2 (pt) 2016-03-15

Family

ID=40792178

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1009922A BRPI1009922A2 (pt) 2009-05-01 2010-04-22 uso de um composto derivado de ácido graxo poli-insaturado,composição farmacêutica,e, método para tratar ou provenir dano nem nervo.

Country Status (14)

Country Link
US (1) US20120122982A1 (enExample)
EP (1) EP2424519A1 (enExample)
JP (1) JP5608220B2 (enExample)
KR (1) KR101664518B1 (enExample)
CN (1) CN102448453B (enExample)
AU (1) AU2010243368C1 (enExample)
BR (1) BRPI1009922A2 (enExample)
CA (1) CA2762009C (enExample)
GB (1) GB0907601D0 (enExample)
MX (1) MX2011011615A (enExample)
NZ (1) NZ596674A (enExample)
SG (1) SG175848A1 (enExample)
WO (1) WO2010125330A1 (enExample)
ZA (1) ZA201108571B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
WO2015071766A1 (en) * 2013-11-15 2015-05-21 Dignity Sciences Limited Pharmaceutically acceptable salts of polyunsaturated hydroxy fatty acids
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE10940T1 (de) * 1981-05-12 1985-01-15 Imperial Chemical Industries Plc Pyrrolderivate.
US4532254A (en) * 1983-03-17 1985-07-30 Kaken Pharmaceutical Co., Ltd. Inhibitor of aldose reductase
KR910005856B1 (ko) * 1987-09-16 1991-08-05 다이호야꾸힝고오교가부시끼가이샤 티에노피리미딘 유도체
DE69433713T2 (de) * 1993-06-09 2005-04-07 Martek Biosciences Corp. Für die behandlung neurologischer erkrankungen nützliche methoden und pharmazeutische zusammensetzungen
US7015249B1 (en) * 1997-12-12 2006-03-21 Purdue Research Foundation Methods and compositions for treating diabetes
US6107349A (en) * 1998-04-16 2000-08-22 Mantynen; Philip R. Method and composition for treating psoriasis
GB9827391D0 (en) * 1998-12-11 1999-02-03 Fundation O N C F Aldose reductase inhibitors and pharmaceutical compositions
CA2304906A1 (en) * 2000-04-07 2001-10-07 1411198 Ontario Limited 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
CZ20023562A3 (cs) * 2000-04-28 2003-03-12 Sankyo Company, Limited PPAR gama modulátory
EP1236720B1 (en) * 2001-02-28 2005-06-15 Pfizer Products Inc. Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors
AU2002304931A1 (en) * 2001-06-08 2002-12-23 University Of British Columbia Methods for treating disorders of the nervous and reproductive systems
CA2480429C (en) * 2002-03-25 2008-09-16 Biosynergen, Inc. Novel therapeutical use of agonist ligands specific to g2a receptor
JP4972745B2 (ja) * 2005-06-22 2012-07-11 国立大学法人群馬大学 Ｇタンパク質共役型受容体ｇ２ａの作動薬、及びｇ２ａ活性調節薬のスクリーニング方法
JP5366211B2 (ja) * 2007-12-18 2013-12-11 国立大学法人富山大学 アルドース還元酵素阻害活性を有する縮合三環化合物

Also Published As

Publication number Publication date
NZ596674A (en) 2013-09-27
EP2424519A1 (en) 2012-03-07
AU2010243368B2 (en) 2013-10-24
AU2010243368C1 (en) 2014-04-03
KR101664518B1 (ko) 2016-10-11
WO2010125330A1 (en) 2010-11-04
KR20120023729A (ko) 2012-03-13
AU2010243368A1 (en) 2011-12-15
SG175848A1 (en) 2011-12-29
CA2762009C (en) 2016-11-22
CN102448453A (zh) 2012-05-09
US20120122982A1 (en) 2012-05-17
MX2011011615A (es) 2012-01-27
CN102448453B (zh) 2016-07-06
JP2012525362A (ja) 2012-10-22
ZA201108571B (en) 2013-01-30
CA2762009A1 (en) 2010-11-04
JP5608220B2 (ja) 2014-10-15
GB0907601D0 (en) 2009-06-10

Similar Documents

Publication Publication Date Title
IL218669A (en) Compounds Effective as Xanthine Oxidase Inhibitors, a Method for their Preparation and Pharmaceuticals Containing Them
BR112012008164A2 (pt) método para a preparação de ácido 2,5-furanodicarbloxílico e seus ésteres
BRPI1008383A2 (pt) composto, composição farmacêutica, método para prevenir, inibir ou tratar uma condição, e, uso de um composto
BR112013015010A2 (pt) produto, substrato, composição farmacêutica, uso de um produto, e, método para tratar uma infecção microbiana
BR112012029227A2 (pt) processo para a preparação de um conjunto quiral, composto quiral, composição, composição farmacêutica, uso de uma composição, método de tratamento ou prevenção e uso de um composto
BRPI0924997A2 (pt) Método para preparar um composto de éster do ácido aril-2-tetrazoil etil carbâmico.
IL203734A (en) Annotations of 6 - Triazolopyridazinesulfonyl Benzothiazole and Benzimidazole, a Method for their Preparation and Use as Medicines and Preparations
BRPI0919937A2 (pt) composto, e, método para melhorar a atividade de adjuvante de uma imidazoquinolina
BRPI0917458A2 (pt) composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
BR112012002780A2 (pt) métodos, compostos, e composições para a aplicação de ácido 1,3-propanodisulfônico
BRPI1013984A2 (pt) composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto.
BR112012022879A2 (pt) composto, composição farmacêutica, uso do composto e método de tratamento
WO2012054862A9 (en) Agents, compositions, and methods for treating pruritis and related skin conditions
BR112012026570A2 (pt) composto, composição farmacêutica, uso de um composto, método para o tratamento de um indíviduo e produto combinado
BRPI0911077A2 (pt) método para tratamento de biomassa
NZ596228A (en) Compositions and methods for the treatment of inflammation
BR112013004456A2 (pt) composição para tratamento de planta, e, método para o tratamento de plantas
BR112012031981A2 (pt) composição aquosa de ingrediente ativo, processo, uso, método para controlar fungos fitopatogênicos e semente
WO2010033292A9 (en) Method for medical treatment utilizing l-glutathione
BRPI0909198A2 (pt) composto antifolato, composto, método para preparar um composto antifolato, composição farmacêutica, método para tratar
WO2010072787A3 (en) A composition comprising a retinoid and method of treating skin conditions
ITTO20110630A1 (it) Composizioni farmaceutiche di combinazione e metodo per trattare vertigini, cinetosi e distonia vascolare vegetativa
KR20180085062A (ko) 피부 상태를 치료하기 위한 조성물 및 방법
BR112012029606A2 (pt) formulação, método para a fabricação de uma fomulação, método de tratamento de uma planta e uso de uma formulação
AU2009290334A8 (en) Method for acquiring highly unsaturated fatty acid derivatives

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]